Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.03 -1.25 (-2.30%)

Streaming Delayed Price Updated: 2:12 PM EDT, Aug 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

36 37 Next >

3 Cathie Wood Stocks to Start Off Your New Year Right ↗

January 10, 2024

The following stocks could deliver big gains over time.

Via The Motley Fool

2 low-priced gene therapy stocks to speculate on

January 08, 2024

Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe

Via MarketBeat

The Ultimate Growth Stock to Buy With $1,000 Right Now ↗

January 08, 2024

The stock, trading for about $60, has plenty of room to run.

Via The Motley Fool

5 Innovative Stocks That Could Score a Win for Your Portfolio in 2024 ↗

January 06, 2024

You'll find exciting innovators across industries.

Via The Motley Fool

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗

January 01, 2024

Via Benzinga

2 Biotech Stocks With Huge Catalysts in 2024 ↗

January 05, 2024

Important clinical-trial readouts on the way could send these stocks soaring in early 2024.

Via The Motley Fool

Gen Z’s Top Picks for 2024: 7 Trending Stocks Among Young Investors ↗

January 04, 2024

Gen Z stocks include companies the generation prefers to invest in while capturing the emerging economic force they represent.

Via InvestorPlace

Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics ↗

January 04, 2024

CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead.

Via The Motley Fool

3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition ↗

January 03, 2024

Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside.

Via InvestorPlace

Better Risky Investment: Bluebird Bio vs. Shiba Inu ↗

January 03, 2024

Few investors dare to tread where the ice is known to be very thin.

Via The Motley Fool

Could CRISPR Therapeutics Stock Help You Become a Millionaire? ↗

December 22, 2023

There are plenty of reasons to be optimistic about CRISPR's future.

Via The Motley Fool

3 Biotech Stocks Set for Breakthroughs in 2024 ↗

January 02, 2024

With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks.

Via InvestorPlace

2 gene-editing stocks reshaping hereditary disease treatments

January 02, 2024

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal

Via MarketBeat

3 No-Brainer Growth Stocks to Buy for Less Than $100 ↗

January 01, 2024

These businesses have promising futures and make for great investment options today.

Via The Motley Fool

1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024 ↗

December 31, 2023

Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name.

Via The Motley Fool

2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics ↗

December 31, 2023

Curing rare inherited illnesses could be a lucrative business model.

Via The Motley Fool

2023 in Review: Nvidia, Interest Rates, Taylor Swift ↗

December 30, 2023

And a little bit of real estate insight.

Via The Motley Fool

3 Stocks That Could Be Monster Winners in 2024 ↗

December 30, 2023

Don't be surprised if these three stocks take off in the new year.

Via The Motley Fool

AI and Automation Leaders for 2024: 7 Stocks to Stay Ahead of the Robot Uprising ↗

December 30, 2023

With the robotics revolution taking over multiple industries, investors have options.

Via InvestorPlace

Topics Artificial Intelligence

CRISPR Therapeutics sets sights on gene-editing cures for disease

December 27, 2023

On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for

Via MarketBeat

3 Top Stocks to Buy Hand Over Fist Before the End of 2023 ↗

December 25, 2023

These are ideal stocks to buy sooner rather than later.

Via The Motley Fool

3 Healthcare Technology Stocks to Improve Lives in 2024 ↗

December 25, 2023

Healthcare technology is one of 2024's top investment trends, and investors looking for long-term upside should check out these top stocks.

Via InvestorPlace

1 Green Flag and 1 Red Flag for Bluebird Bio Stock ↗

December 23, 2023

The stock has been in the news lately.

Via The Motley Fool

Cathie Wood Predicts Deflation In 2024, More AI And Tech Optimism — And Rate Cuts ↗

December 22, 2023

Cathie Wood believes deflation in 2024, aggressive rate cuts and technological progress will drive expansion.

Via Benzinga

Topics Artificial Intelligence Economy

3 Money-Saving Tricks for Investing in Biotech Stocks in 2024 ↗

December 22, 2023

Doing a little math and doing a little extra research can make a big difference.

Via The Motley Fool

I'm Begging You to Buy Stocks Before January -- Here's Why ↗

December 22, 2023

Some studies have shown a pattern of market gains in the month of January.

Via The Motley Fool

Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock? ↗

December 22, 2023

The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction.

Via The Motley Fool

6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy ↗

December 21, 2023

Should you buy CRISPR's stock on the dip?

Via The Motley Fool

Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock ↗

December 21, 2023

These stocks are currently going in different directions, but both could go up in a new bull market.

Via The Motley Fool

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.